Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical study titled ‘A Phase 2b/3, ...

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called ...

The pharmaceutical giant has granted the president’s long-standing demands. Other drug companies could be next.

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend ...

In a gripping new release from Skyhorse Publishing, molecular biologist and whistleblower Becky McClain lays bare her harrowing journey in "Exposed," a book that promises to shake the foundations of ...

One Louisiana woman, Robin Phillip, said she developed an intracranial meningioma that caused her to lose vision in her left ...

Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.

Pfizer faces lawsuits from 1,000 women alleging Depo-Provera birth control caused brain tumours, amid new research showing ...

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer made a deal with the administration to implement President Donald Trump's Most Favored Nation drug pricing policies.

If approved alongside current SoC maintenance therapies, Tukysa could become the first update to the regimen for ...